Evidence map›Paper›PMID 39248552›Full record

ArticleGenes, chromosomes & cancer2024

Molecular Analysis of Renal/Adrenal Angiosarcomas Reveals High Frequency of Recurrent Genetic Alterations.

Pedram Argani, Carla Saoud, Cristina R Antonescu

Abstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Pedram ArganiDepartment of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.ORCID 0000-0001-8797-9474
Carla SaoudDepartment of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Cristina R AntonescuDepartment of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.ORCID 0000-0002-9717-8205

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI William D. Tap · 2018 to 2026
$21.5M
Angiosarcoma AwarenessCycle for SurvivalDahan Translocation Carcinoma Fund and Joey's WingsKen Pribil FoundationKristin Ann Carr FoundationNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694P30 CA008748P50 CA217694
6 · The paper itself

Abstract

Angiosarcomas of the kidney and adrenal gland are rare, highly aggressive vascular neoplasms. Their genomic profile has not been systematically studied to date. We report the clinicopathologic and molecular features of six angiosarcomas centered in the kidney/adrenal gland. All patients were male adults, ranging from 58 to 77 years of age. Tumor sizes ranged from 2.5 to 22.5 cm. Half of the cases demonstrated hot spot mutations in the KDR gene, while one-third demonstrated mutations in the PIK3CA gene; both of these gene alterations being previously described, preferentially in breast angiosarcomas. In addition, two cases each demonstrated BRIP1 gene amplification, CTNNB1 and ETV6 mutations, which have not been previously reported in angiosarcoma. Notably, molecular studies were critical in establishing the correct diagnoses in three cases: one was an epithelioid angiosarcoma originally misdiagnosed as metastatic adenocarcinoma to the adrenal gland, the second was a vasoformative angiosarcoma that mimicked hemangioma, and the third was a collision tumor between a high-grade angiosarcoma and a chromophobe renal cell carcinoma which was originally diagnosed as a sarcomatoid renal cell carcinoma. In summary, angiosarcomas of the kidney and adrenal gland have a high frequency of recurrent genetic alterations, some of them being shared with other angiosarcoma subtypes, while other appear to be novel. In particular, activating hot spot KDR and PIK3CA mutations represent potential therapeutic targets for these highly aggressive cancers.

Indexed as

Adrenal Gland NeoplasmsClass I Phosphatidylinositol 3-KinasesHemangiosarcomaKidney NeoplasmsMutationAgedbeta CateninDNA-Binding ProteinsETS Translocation Variant 6 ProteinHumansMaleMiddle AgedPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-etsRepressor ProteinsVascular Endothelial Growth Factor Receptor-2beta CateninClass I Phosphatidylinositol 3-KinasesCTNNB1 protein, humanDNA-Binding ProteinsETS Translocation Variant 6 ProteinKDR protein, humanPhosphatidylinositol 3-KinasesPIK3CA protein, humanProto-Oncogene Proteins c-etsRepressor ProteinsVascular Endothelial Growth Factor Receptor-2adrenalangiosarcomagenomicskidneymutationnext generation sequencing

Identifiers

PMID39248552
PMCPMC12118094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.